Idebenone
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Idebenone: From Mitochondrial Disorders to Hepatic Porphyria
One-Sentence Summary
Idebenone is a coenzyme Q10 (ubiquinone) analog with known clinical use in mitochondrial energy metabolism support (e.g., Friedreich’s ataxia, mitochondrial myopathies), though this evidence pack contains no formal record of an approved original indication for the drug. The TxGNN model predicts it may be effective for hepatic porphyria, but this is currently a pure model prediction with zero clinical trials and zero publications supporting the link.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not on file in this evidence pack (drug not marketed in the EU; known clinical use in mitochondrial disorders per literature context, not formally documented here) |
| Predicted New Indication | Hepatic porphyria |
| TxGNN Prediction Score | 99.92% |
| Evidence Level | L5 |
| EU Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the formal MOA field. Based on the repurposing rationale provided, Idebenone is a coenzyme Q10 (ubiquinone) analog that acts on the mitochondrial electron transport chain and exhibits antioxidant activity. This mechanism underlies its known clinical use in conditions involving mitochondrial energy deficits, such as Friedreich’s ataxia and mitochondrial myopathies.
No original indication or EU marketing data exists in this evidence pack (0 licenses, market status “not marketed”), so the relationship between any prior approved use and hepatic porphyria cannot be established from regulatory data alone.
Mechanistically, hepatic mitochondrial oxidative stress has a theoretical connection to acute porphyria attacks, which is the basis for this TxGNN prediction. However, the evidence pack explicitly flags this as a hypothesis derived from knowledge-graph similarity (score clustering around 0.999 across several unrelated hepatic/portal diseases), rather than an experimentally or clinically supported mechanism — it may reflect a graph-clustering artifact around “liver-related” nodes rather than true pharmacological relevance.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
EU Market Information
Idebenone currently holds no EU marketing authorizations on record (0 licenses; market status: not marketed).
Safety Considerations
Please refer to the SmPC for safety information.
Note: A blocking data gap exists — TFDA label warnings/contraindications (DG001) are required before this candidate can proceed to safety screening (S1).
Conclusion and Next Steps
Decision: Hold
Rationale: This prediction is supported only by TxGNN model similarity scoring (L5) with no corroborating clinical trials or literature across any of the 10 predicted indications, and a blocking data gap exists for basic drug safety labeling. There is currently no evidentiary basis to advance beyond hypothesis generation.
To proceed, the following is needed:
- TFDA/EMA label warnings, contraindications, and DDI data (resolves blocking gap DG001)
- Confirmed original indication and mechanism of action from DrugBank or regulatory sources (resolves DG002)
- Preclinical or mechanistic studies specifically linking Idebenone to hepatic porphyria pathophysiology
- Ongoing monitoring for any emerging clinical trials or publications on this drug-disease pair
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.